bioAffinity Technologies公司宣布,已启动一项针对其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究。该研究旨在通过长期跟踪和数据收集,进一步验证该诊断方法的有效性与可靠性。
bioAffinity Technologies公司宣布,已启动一项针对其非侵入性Cypath®肺癌诊断技术的大规模纵向临床研究。该研究旨在通过长期跟踪和数据收集,进一步验证该诊断方法的有效性与可靠性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.